ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ORKA vs NEOG // EV/EBITDA & P/E VALUATION

Oruka Therapeutics Inc. (NASDAQ) VS. Neogen Corporation (NASDAQ) • 15-METRIC TALLY: ORKA 3 — NEOG 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ORKA VS. NEOG) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ORKA NEOG SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 46.90% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -18.80% -0.60% -18.20 NEOG /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -1.38% 3.11% -4.49 NEOG /fcf-yield <GO>
Operating Margin -6.80% -2.50% -4.30 NEOG /operating-margins <GO>
Net Profit Margin -5.90% -0.90% -5.00 NEOG /net-margins <GO>
Revenue Growth (YoY) -4.40% -2.70% -1.70 NEOG /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 26.00 1.45 +24.55 ORKA /balance-sheet <GO>
Piotroski F-Score Quality 4/9 7/9 -3.00 NEOG /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 66.7 45.3 +21.45 ORKA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 1.13 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 28.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $6.40B $2.68B $3.72B ORKA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ORKA REV NEOG REV ORKA GROSS % NEOG GROSS % ORKA FCF NEOG FCF
FY 2025 $0 $870.4M — 46.9% -$88.4M $83.2M
FY 2024 $0 $894.7M — 47.1% -$58.0M $58.2M
FY 2023 $0 $924.2M — — -$5.0M $35.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ORKA // BETA 1.13
NEOG // BETA —